Home/Filings/4/0001567619-18-007897
4//SEC Filing

BAUPOST GROUP LLC/MA 4

Accession 0001567619-18-007897

CIK 0001114220other

Filed

Dec 12, 7:00 PM ET

Accepted

Dec 13, 4:02 PM ET

Size

15.9 KB

Accession

0001567619-18-007897

Insider Transaction Report

Form 4
Period: 2018-12-11
Transactions
  • Award

    Common Stock

    2018-12-11$4.63/sh+35,582,335$164,746,21161,374,013 total(indirect: See footnote 1 and 2)
  • Award

    Common Stock

    2018-12-11+4,000,00065,374,013 total(indirect: See footnote 1 and 2)
  • Disposition to Issuer

    Common Stock

    2018-12-1265,374,0130 total(indirect: See footnote 1 and 2)
  • Exercise/Conversion

    Zero Coupon Senior Convertible Notes due 2021

    2018-12-110 total(indirect: See footnote 1 and 2)
    Exercise: $4.63From: 2018-05-09Exp: 2021-10-15Common Stock (35,582,335 underlying)
Transactions
  • Award

    Common Stock

    2018-12-11$4.63/sh+35,582,335$164,746,21161,374,013 total(indirect: See footnote 1 and 2)
  • Award

    Common Stock

    2018-12-11+4,000,00065,374,013 total(indirect: See footnote 1 and 2)
  • Disposition to Issuer

    Common Stock

    2018-12-1265,374,0130 total(indirect: See footnote 1 and 2)
  • Exercise/Conversion

    Zero Coupon Senior Convertible Notes due 2021

    2018-12-110 total(indirect: See footnote 1 and 2)
    Exercise: $4.63From: 2018-05-09Exp: 2021-10-15Common Stock (35,582,335 underlying)
Transactions
  • Award

    Common Stock

    2018-12-11$4.63/sh+35,582,335$164,746,21161,374,013 total(indirect: See footnote 1 and 2)
  • Award

    Common Stock

    2018-12-11+4,000,00065,374,013 total(indirect: See footnote 1 and 2)
  • Disposition to Issuer

    Common Stock

    2018-12-1265,374,0130 total(indirect: See footnote 1 and 2)
  • Exercise/Conversion

    Zero Coupon Senior Convertible Notes due 2021

    2018-12-110 total(indirect: See footnote 1 and 2)
    Exercise: $4.63From: 2018-05-09Exp: 2021-10-15Common Stock (35,582,335 underlying)
Footnotes (4)
  • [F1]This statement on Form 4 is being jointly filed by The Baupost Group, L.L.C. ("Baupost"), Baupost Group GP, LLC ("Baupost GP") and Seth A. Klarman ("Mr. Klarman") (collectively, the "Reporting Persons"). Baupost is a registered investment adviser. The principal business of Baupost is to act as an investment adviser to various private investment limited partnerships. Baupost GP, as the manager of Baupost, and Mr. Klarman, as the sole managing member of Baupost GP and a controlling person of Baupost, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), of the securities beneficially owned by Baupost. Securities reported on this Form 4 as being beneficially owned by Baupost were purchased on behalf of certain of such partnerships.
  • [F2](Continued from footnote 1) The Reporting Persons disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that the Reporting Persons are the beneficial owners thereof for purposes of Section 16 of the Exchange Act or for any other purpose.
  • [F3]Pursuant to the terms of the Notes Conversion Agreement, dated as of June 28, 2018, by and among Keryx Biopharmaceuticals, Inc., Baupost Group Securities, L.L.C. and, with respect to certain sections only, Akebia Therapeutics, Inc., Baupost Group Securities, L.L.C. agreed to convert its Zero Coupon Senior Convertible Notes due 2021 pursuant to the terms of the governing indenture in exchange for, among other things, the receipt of 4,000,000 share of Common Stock.
  • [F4]Pursuant to the terms of the Merger Agreement, dated as of June 28, 2018, by and among Keryx Biopharmaceuticals, Inc., Akebia Therapeutics, Inc. and Alpha Therapeutics Merger Sub Inc., upon the closing of the Merger specified therein, all shares of Common Stock held by the Reporting Persons (including all shares of Common Stock issued pursuant to the terms of the Notes Conversion Agreement) converted into common stock, par value $0.00001 per share, of Akebia Therapeutics, Inc.

Documents

1 file

Issuer

KERYX BIOPHARMACEUTICALS INC

CIK 0001114220

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001061768

Filing Metadata

Form type
4
Filed
Dec 12, 7:00 PM ET
Accepted
Dec 13, 4:02 PM ET
Size
15.9 KB